<SEC-DOCUMENT>0001104659-26-071211.txt : 20260608
<SEC-HEADER>0001104659-26-071211.hdr.sgml : 20260608
<ACCEPTANCE-DATETIME>20260608090147
ACCESSION NUMBER:		0001104659-26-071211
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20260608
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260608
DATE AS OF CHANGE:		20260608

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MetaVia Inc.
		CENTRAL INDEX KEY:			0001638287
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472389984
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37809
		FILM NUMBER:		261071168

	BUSINESS ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138
		BUSINESS PHONE:		(857) 702-9600

	MAIL ADDRESS:	
		STREET 1:		545 CONCORD AVENUE
		STREET 2:		SUITE 210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NeuroBo Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20191231

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Gemphire Therapeutics Inc.
		DATE OF NAME CHANGE:	20150331
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>mtva-20260608x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.3.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 6/2/2026 7:16:22 PM -->
<!-- iXBRL Library version: 1.0.9561.79 -->
<!-- iXBRL Service Job ID: 00000000-0000-0000-0000-000000000000 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:mtva="http://metaviatx.com/20260608" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title>METAVIA INC._June 8, 2026</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityCentralIndexKey" id="Tc_SqoopIkrAE6Z1ixaaFMt5A_1_1">0001638287</ix:nonNumeric><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:AmendmentFlag" id="Tc_-h9RUMcCy0WMOpzyVhBNLg_2_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="mtva-20260608.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001638287</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-06-08</xbrli:startDate><xbrli:endDate>2026-06-08</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:41.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1px solid #000000;border-top:2.25pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><a id="_a8cfc5aa_7156_42e9_b20f_3ae014dc0fb5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:DocumentType" id="Narr_YjU5VP2J6UeypbemS0By9w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="Narr_zooDrWazp0yv8FMlORHesQ"><b style="font-weight:bold;">June 8, 2026</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="mtva-20260608x8k001.jpg" alt="Graphic" style="display:inline-block;height:41.04pt;width:214.56pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityRegistrantName" id="Narr_1MDtTkcDF0iYNLARDXagnw"><b style="font-weight:bold;">METAVIA INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-size:7.5pt;font-weight:bold;">(Exact name of Registrant as Specified in Its Charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_13452a04_9467_4692_bd89_690379252b8f"></a><a id="Tc_hBmIggE3U0-LofTzLd8M9Q_2_0"></a><a id="Tc_Dwv7h7HMWEG-J64dnJYBaw_2_2"></a><a id="Tc_BDibUmiR4EKOR9d7ufm59g_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_1H_O2LZS5kGy6UozS1u65Q_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityFileNumber" id="Tc_bMXOiZLJckmy1rip9B51wQ_1_2"><b style="font-weight:bold;">001-37809</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityTaxIdentificationNumber" id="Tc_hgKFsw_nH0KFCLOzXjlhEg_1_4"><b style="font-weight:bold;">47-2389984</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or other jurisdiction</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">of incorporation)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Commission</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:top;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(IRS Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_a03c4018_f776_4435_ac00_d380f9b56282"></a><a id="Tc_tfsu4gkaz0GVkw2YMgipOA_1_0"></a><a id="Tc_qrW-JdsCFkWqqA3uN2rAAA_2_0"></a><a id="Tc_baTXFWLXjUq20HwLYurgCQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityAddressAddressLine1" id="Narr_S-7nqFAyMEyRkoUlv5LjAw"><b style="font-size:9pt;font-weight:bold;">545 Concord Avenue</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityAddressAddressLine2" id="Narr_Vy62P6rZSUOliaXrouUT4A"><b style="font-size:9pt;font-weight:bold;">Suite 210</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityAddressCityOrTown" id="Narr_s32JPmU-BEqdZxPYEqfCUg"><b style="font-size:9pt;font-weight:bold;">Cambridge</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_IIq8c3NjKUelN6LkTFTI7g"><b style="font-size:9pt;font-weight:bold;">Massachusetts</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:EntityAddressPostalZipCode" id="Tc_Qmc3ip2T1UuU8uZOM-cgMQ_1_2"><b style="font-size:9pt;font-weight:bold;">02138</b></ix:nonNumeric></p></td></tr><tr style=""><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:49.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:CityAreaCode" id="Narr_FcmgICg0SU-tgq-1XbYy6g"><b style="font-weight:bold;">857</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:LocalPhoneNumber" id="Narr_aTgjmJJf_EySkyGw69ZHaQ"><b style="font-weight:bold;">702-9600</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name or former address, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_e51ff3d8_d6f6_44c9_b338_8f565e4a1604"></a><a id="Tc_v4adM548x0eWLbT0w1rCvA_1_1"></a><a id="Tc_Ps16SpIuv0WTNBqlYrGddA_2_1"></a><a id="Tc_iZZx8WoyPE-tC7YwqRV5FQ_3_1"></a><a id="Tc_fUiGxUx8JUSjCZFwNztA4w_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Tc_3HtLSBcsN0eC2LhvoVkVuw_1_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr><tr style=""><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Tc_6cZmtYlLtEuLk2g3y0gAPQ_2_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr><tr style=""><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Tc_RTpuoD_Iz0uSMTCaAPK8Dg_3_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr><tr style=""><td style="vertical-align:top;width:3.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Tc_Oxjp6qu_HU6UdynmXrDOPw_4_0"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_0c311cdb_c736_4079_9d07_0deae2867d84"></a><a id="Tc_-aEioYfa8UCX01-tSktFhA_1_0"></a><a id="Tc_023KQU9kUEKTz6oG6BotgQ_1_2"></a><a id="Tc_HJ31ExIfmU2T9NGJFMN2kg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:39.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:14.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:41.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:39.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:14.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Symbol(s)</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td style="vertical-align:bottom;width:41.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style=""><td style="vertical-align:top;width:39.74%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:Security12bTitle" id="Tc_wPjTheSf7UmqrX1fcvMHGg_2_0">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:14.66%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" name="dei:TradingSymbol" id="Tc_fHL5uVN3k0OdOklrUUwzIQ_2_2">MTVA</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:41.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_xt7saI8W30i9T08lhtf95w_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emerging growth company&#160;<ix:nonNumeric contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_jGmNcBDe40qw5DnSFTw9vQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:2.25pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_764cec70_67f2_42eb_9696_f748148f0b07"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 7.01.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span></span><b style="font-weight:bold;background:#ffffff;">Regulation FD Disclosures.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">On June 8, 2026, MetaVia Inc. (the &#8220;Company&#8221;) issued a press release announcing <span style="font-family:'Calibri','Helvetica','sans-serif';">th</span>e presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association&#8217;s (ADA) 2026 Scientific Sessions, held June 5&#8211;8 in New Orleans, Louisiana. The presentations included new Phase 1 higher-dose cohort results for DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), as well as preclinical data supporting combination treatment potential for vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, in metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2D) and obesity. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K (this &#8220;Report&#8221;) and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The information in Item 7.01 of this Report, including Exhibit 99.1 attached hereto, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the&#160;Securities Exchange Act of 1934, as amended (the&#160;&#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the&#160;Securities Act of 1933, as amended, or the&#160;Exchange Act, except as expressly set forth by specific reference in such filing. The Company&#8217;s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of&#160;Regulation FD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt -20.15pt 0pt 0pt;"><span style="font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_80f09c72_9eb5_4b89_8adf_2c5027366079"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 8.01. </b></span><b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">On June 8, 2026, the Company presented the following late-breaking data in poster presentations highlighting its obesity and metabolic disease portfolio at the ADA 2026 Scientific Sessions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">DA-1726</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">The late-breaking poster presentation of DA-1726 reported interim results from a randomized, double-blind, placebo-controlled Phase 1 multiple ascending dose study evaluating once-weekly subcutaneous administration in obese but otherwise healthy adults. In the 48 mg cohort, DA-1726 was generally well tolerated, with predominantly mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events. Pharmacokinetic (PK) analysis demonstrated sustained exposure with dose-proportional behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">DA-1726 produced a 6.1% reduction in body weight at Day 26 and a 9.1% reduction at Day 54 (p&lt;0.05 vs placebo at Day 26), with continued reductions through Week 8 and no evidence of plateau. Waist circumference was reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p&lt;0.05 vs placebo), with accompanying reductions in BMI of 2.3 kg/m&#178; and 3.4 kg/m&#178; at Day 22 and Day 54, respectively. These clinically meaningful, statistically significant body weight reductions at higher doses were consistent with the dose-proportional PK profile and support continued development for obesity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;">Vanoglipel</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The late-breaking preclinical study evaluating vanoglipel in combination with resmetirom demonstrated synergistic hepatoprotective and weight-loss effects in a biopsy-confirmed diet-induced obese mouse model of MASH. While monotherapies had no significant effect on body weight, combination treatment achieved a 23.6% reduction versus control (p&lt;0.05), with endpoint fat mass and epididymal fat weight reduced by 43.5% and 42.1%, respectively. All treatments decreased ALT, with the largest reduction rate of 83.5% in the combination group. Histopathologic assessment showed significant improvements in hepatic lipid accumulation, inflammation and fibrosis-related biomarkers. The study represents the first demonstration of the therapeutic potential of combined targeting of GPR119 and thyroid hormone receptor beta (THR&#946;) for MASH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">The late-breaking preclinical study evaluating vanoglipel in combination with metformin demonstrated greater metabolic and weight effects than either monotherapy in a diet-induced obese mouse model with mild hyperglycemia. Combination treatment reduced non-fasting glucose by 28.7% (p&lt;0.05) and fasting glucose by 22.7% versus control. While each monotherapy reduced body weight by approximately 4%, the combination achieved a 16.3% reduction versus control (p&lt;0.05). Fat mass increased by 0.4-1.4 g from baseline in the control and monotherapy groups but decreased by 3.6 g in the combination group (-25.6% vs baseline, p&lt;0.05). These effects were accompanied by increases in total GLP-1 and </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">peptide YY (PYY) levels of 6.4-fold and 1.5-fold, respectively, along with reduced food intake, supporting enhanced gut hormone&#8211;mediated metabolic activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_bd9bc5dc_1d19_4eec_8003_baf1950bdbe8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:54pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 9.01. </b></span><b style="font-weight:bold;">Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">(d) Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:0.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:89.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:9.51%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit<br/>Number</p></td><td style="vertical-align:bottom;width:0.73%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:89.75%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exhibit Description</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:0.73%;background:#cceeff;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:89.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="mtva-20260608xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release dated June 8, 2026.</span></a></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:0.73%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:89.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (embedded within Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;background:#000000;margin:0pt 0pt 8pt 0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 3.6pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_86d7d8b6_f0a0_4d5c_b50c_f36b89c0a653"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signatures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#8203;&#160;&#8203;&#160;&#8203;</p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">METAVIA INC.</b></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt -14pt;">Date: June 8, 2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By: </p></td><td style="vertical-align:bottom;width:45.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Hyung Heon Kim</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hyung Heon Kim</p></td></tr><tr style=""><td style="vertical-align:bottom;width:48.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:45.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>mtva-20260608xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.2.0.21--><!--Created on: 6/2/2026 07:16:22 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:66pt;left:14.38%;max-width:85.62%;position:absolute;top:-38.5pt;width:342.17pt;z-index:251658240;"><div style="height:65.5pt;left:0pt;padding-bottom:0.5pt;position:relative;width:342.17pt;"><img src="mtva-20260608xex99d1001.jpg" alt="Graphic" style="height:65.5pt;width:342.17pt;"></div></div></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:57.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;">MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">DA-1726 Phase 1, 48 mg Cohort Achieved Up to 9.1% Mean Body Weight Reduction at Day 54 Without Evidence of Plateau</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Vanoglipel Combined with Resmetirom Demonstrated Synergistic Hepatoprotective and Weight-Loss Effects in Preclinical MASH Model</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="color:#201f1e;font-family:'Calibri','Helvetica','sans-serif';font-style:italic;">Vanoglipel Combined with Metformin Demonstrated Enhanced Glycemic Control and Body Weight Reduction Versus Monotherapy in a Preclinical T2D Model</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">CAMBRIDGE, Mass., June 8, 2026 &#8211; MetaVia Inc. </b><font style="font-family:'Calibri','Helvetica','sans-serif';">(Nasdaq: MTVA),</font><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"> </b><font style="font-family:'Calibri','Helvetica','sans-serif';">a clinical-stage biotechnology company focused on transforming cardiometabolic diseases</font><font style="font-family:'Calibri','Helvetica','sans-serif';">, today announced the presentation of new late-breaking data highlighting its obesity and metabolic disease portfolio at the American Diabetes Association&#8217;s (ADA) 2026 Scientific Sessions, held June 5&#8211;8 in New Orleans, Louisiana. The presentations included new Phase 1 higher-dose cohort results for DA-1726, a novel dual agonist targeting glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), as well as preclinical data supporting combination treatment potential for vanoglipel (DA-1241), a novel G-protein-coupled receptor 119 (GPR119) agonist, in metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2D) and obesity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The data highlighted favorable safety, tolerability and clinically meaningful reductions in body weight and waist circumference for DA-1726 at the 48 mg dose level, while the vanoglipel presentations demonstrated synergistic metabolic, liver-related effects and weight loss when combined with current standards of care, supporting potential combination strategies across MASH, T2D and obesity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;The late-breaking ADA 2026 data further reinforces the differentiated and complementary potential of our cardiometabolic pipeline,&#8221; said Hyung Heon Kim, President and Chief Executive Officer of MetaVia. &#8220;DA-1726 demonstrated clinically meaningful and progressive weight loss up to 9.1% at the 48 mg dose level without evidence of plateau, along with consistent reductions in waist circumference and BMI in a once-weekly regimen without titration. Importantly, the data also demonstrates a sustained and progressive metabolic effect through Day 54, supporting continued advancement of higher-dose evaluation in our ongoing Phase 1 Part 3 titration studies designed to assess higher-dose exposure and durability of metabolic response, with results expected in the fourth quarter of 2026.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">&#8220;In parallel, preclinical vanoglipel combination data demonstrated synergistic effects across liver and metabolic disease models, including meaningful improvements in hepatic steatosis, liver injury markers, fibrosis-related biomarkers, glycemic control, and body weight. Importantly, when combined with resmetirom, vanoglipel&#8217;s ability to unlock synergistic benefits highlights its potential as a combination strategy for MASH. In addition, when combined with metformin, vanoglipel improved glycemic control and reduced body weight to a greater extent than either monotherapy, further supporting its potential as a therapeutic combination strategy for additional metabolic benefit in T2D. Taken together, these findings </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">further support DA-1726 as a differentiated obesity therapy and vanoglipel as a versatile metabolic backbone for combination approaches in MASH and type 2 diabetes.&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';"> </font><font style="font-size:12pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Title: </b><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue: Phase 1 Higher-Dose Cohort Results</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Presenting Author:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Weikai &#8220;Chris&#8221; Fang, Chief Medical Officer, MetaVia </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Abstract Control Number:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> 3102-LB</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Session: </b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">23-B Obesity&#8212;Human</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The late-breaking poster presentation of DA-1726 reported interim results from a randomized, double-blind, placebo-controlled Phase 1 multiple ascending dose study evaluating once-weekly subcutaneous administration in obese but otherwise healthy adults. In the 48 mg cohort, DA-1726 was generally well tolerated, with predominantly mild-to-moderate and transient gastrointestinal adverse events and no treatment-related discontinuations or serious adverse events. Pharmacokinetic (PK) analysis demonstrated sustained exposure with dose-proportional behavior.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">DA-1726 produced a 6.1% reduction in body weight at Day 26 and a 9.1% reduction at Day 54 (p&lt;0.05 vs placebo at Day 26), with continued reductions through Week 8 and no evidence of plateau. Waist circumference was reduced by 5.8 cm at Day 22 and 9.8 cm at Day 54 (p&lt;0.05 vs placebo), with accompanying reductions in BMI of 2.3 kg/m&#178; and 3.4 kg/m&#178; at Day 22 and Day 54, respectively. These clinically meaningful, statistically significant body weight reductions at higher doses were consistent with the dose-proportional PK profile and support continued development for obesity.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Title: </b><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">Synergistic Hepatoprotective and Weight-Loss Effects of Vanoglipel and Resmetirom Combination Therapy in a Diet-Induced Obese, Biopsy-Confirmed Mouse Model of MASH</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Presenting Author:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Yuna Chae, Lead Research Scientist, Dong-A ST Research Center </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Abstract Control Number:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> 3043-LB</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Session: </b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">22-C Integrated Physiology&#8212;Liver </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The late-breaking preclinical study evaluating vanoglipel in combination with resmetirom demonstrated synergistic hepatoprotective and weight-loss effects in a biopsy-confirmed diet-induced obese mouse model of MASH. While monotherapies had no significant effect on body weight, combination treatment achieved a 23.6% reduction versus control (p&lt;0.05), with endpoint fat mass and epididymal fat weight reduced by 43.5% and 42.1%, respectively. All treatments decreased ALT, with the largest reduction rate of 83.5% in the combination group. Histopathologic assessment showed significant improvements in hepatic lipid accumulation, inflammation and fibrosis-related biomarkers. The study represents the first demonstration of the therapeutic potential of combined targeting of GPR119 and thyroid hormone receptor beta (THR&#946;) for MASH.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Title: </b><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;">Synergistic Effects of Vanoglipel and Metformin on Glycemic Control and Body Weight Reduction in a Diet-Induced Obese Mouse Model</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Presenting Author:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> Tae Hyoung Kim, Lead Research Scientist, Dong-A ST Research Center</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Abstract Control Number:</b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"> 2856-LB</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:bold;">Session: </b><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;">12-D Clinical Therapeutics&#8212;Other Therapeutic Agents</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';">The late-breaking preclinical study evaluating vanoglipel in combination with metformin demonstrated greater metabolic and weight effects than either monotherapy in a diet-induced obese mouse model with mild hyperglycemia. Combination treatment reduced non-fasting glucose by 28.7% (p&lt;0.05) and fasting glucose by 22.7% versus control. While each monotherapy reduced body weight by approximately 4%, the combination achieved a 16.3% reduction versus control (p&lt;0.05). Fat mass increased by 0.4-1.4 g from baseline in the control and monotherapy groups but decreased by 3.6 g in the combination group (-25.6% vs baseline, p&lt;0.05). These effects were accompanied by increases in total GLP-1 and peptide YY (PYY) levels of 6.4-fold and 1.5-fold, respectively, along with reduced food intake, supporting enhanced gut hormone&#8211;mediated metabolic activity.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:14pt 0pt 0pt 0pt;">A copy of the posters will be available on the&#160;Posters&#160;section of the MetaVia website after the presentation.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About DA-1726</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">DA-1726 is a novel GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in preclinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy&#174;), a leading GLP-1 receptor agonist. Additionally, in preclinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound&#174;) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About Vanoglipel (DA-1241)</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Vanoglipel is a once daily, orally available G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes (T2D). Agonism of GPR119 in the pancreas stimulates glucose-dependent insulin secretion, and in the gut, it promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further role in glucose metabolism, lipid metabolism and weight loss. Vanoglipel has beneficial effects on glucose, lipid profile and liver pathology including steatosis, inflammation and fibrosis, supported by potential efficacy demonstrated during in vivo preclinical studies. The therapeutic potential of vanoglipel has been demonstrated in multiple animal models of MASH and T2D where vanoglipel reduced hepatic steatosis, inflammation, fibrosis, and improved glucose control. Furthermore, in Phase&#160;1a and 1b trials, vanoglipel was well tolerated in both healthy volunteers and those with T2DM. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">About MetaVia</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP-1 receptor agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a potential first-in-class drug candidate </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">targeting G-protein-coupled receptor 119 (GPR119). In preclinical studies, vanoglipel demonstrated a positive metabolic effect on glucose and lipid control, and also proved differentiated hepatic benefits reducing hepatic steatosis, hepatic inflammation, and liver fibrosis regardless independent of metabolic improvement. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">For more information, please visit www.metaviatx.com.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &quot;believes&quot;, &quot;expects&quot;, &quot;anticipates&quot;, &quot;may&quot;, &quot;will&quot;, &quot;should&quot;, &quot;seeks&quot;, &quot;approximately&quot;, &#8220;potential&#8221;, &quot;intends&quot;, &quot;projects&quot;, &quot;plans&quot;, &quot;estimates&quot; or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia&#39;s history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia&#8217;s ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia&#39;s current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia&#39;s contract manufacturers, clinical study partners and others involved in the development of MetaVia&#39;s current and future product candidates; potential negative interactions between MetaVia&#39;s product candidates and any other products with which they are combined for treatment; MetaVia&#39;s ability to initiate and complete clinical trials on a timely basis; MetaVia&#39;s ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia&#39;s clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia&#39;s stock price; and other risks and uncertainties described in MetaVia&#39;s filings with the Securities and Exchange Commission, including MetaVia&#39;s most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Contacts:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;">MetaVia</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Marshall H. Woodworth</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Chief Financial Officer</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">+1-857-299-1033</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">marshall.woodworth@metaviatx.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="margin-bottom:8pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-line:none;">Rx Communications Group</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">Michael Miller</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">+1-917-633-6086</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;">mmiller@rxir.com</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>mtva-20260608x8k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20260608x8k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !3 :X# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@#C?%GQ?\ "7@;7K#1M;U=++4;W'E1&-VX)P"Q4$*">.<5V/6O@3]L;61?
M?&F5(FPUE:0PG!Z,"S?^S"OKOX#>.%\?_"W1-29E-RD0MK@*<XD3CGW(P?QK
MUL3@?8X:G7C]K?\ 0^4R[.GC,QQ&!FDN1^[;JEH[_,]!HHI"0 23@"O)/JQ:
M*\)\2_M4:;IGQ#M/#FE:<=8MVG6VN+R.7&URV,(,'=CN<U[J#D5U5\+6PZC*
MK&W,KH\G YK@\RG5AA*G,Z;M*U[)^NS^5Q:***Y3U@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#B?B'\9O!_PJN-.@\3ZS'IDNH,5
M@0QO(2!U8[0=JC(Y/%=7I6K66NZ=!?Z==P7]C<+OBN;:021R+ZAAP:\%_;'^
M!K_%'P0NMZ5$7\0Z$CRQQ*,FY@ZR1@9^\,;AUZ$?Q5\._"WXW>+O@_J(N/#V
MINEJS!IM/GR]M-_O)G@_[0P?>O;P^7QQ=#GI2]];IGP^8<05<IQ[HXJG>E*S
MBUOYWZ/7IH?K/17S]\&/VR/"/Q+\C3M8=/"^OL ODW4@^SS-C_EG*< 9_NM@
M] ":]_=PD;/V S7E5:-2A+DJ*S/J\)C</CJ?M</-27];KI\S\V?VC;L7OQL\
M5R!MP^TA<_1%']*]A_8<\=BUU;5O"EQ*JI=)]JME;J77[P'X<_A7SQ\1K]M4
M\?\ B.Z8[O-U"<@^WF$#],5-\,?%\O@3QYHVMQ/M%M<*9/0H3A@?;%?H-;#>
MVP7L>ME]Z/P3"9C]4SCZWT<W?T;=_P &?J17S'^TM^T'_9ZW'A/PU<XN6!2^
MO86_U8[QJ1W]3^%:?[0G[1=OH&E#0_#%T)M4O(5>2[CY%O&PR,?[9!_"OCR2
M1I79W8N['+,QR2?6O/R7*.=K%8A:=%^K_0]7CCC'V*EE>73]YZ3DNG]U/OW?
M3;?;U;]F3PM_PD_Q9TYW)\FP#7;Y&02. #]2?TK[VKYJ_8N\*M:Z%K.ORQ@&
MZD%O$WJJ\G]37TK7EY]7]MC7%;15O\SZKP_P'U+)(5)+WJK<OELOP5_F%%%%
M?.'Z2%%%% !1110 45'<OY=O*_\ =4G]*_G7\?\ B*;5OB1XDUF&9@]UJUS=
MHZMW:9G!'YT#2N?T645X=^QK\=$^/OP'T+79IE?6[1/[/U1-Y9OM$8 WG//S
MKM?ZL1VKW&@0445QGQC^)>G_  @^&?B'Q;J4BI!IEJ\JJS &23'R(,]23CB@
M#LZ*_G*\8^-=4\<>,-5\2:G<R3ZCJ%T]U*[N6.YCG&?0< >PK^@'X+:Y#XE^
M$?@[4K=BT-QI5NP)[XC /Z@T#:L=I1110(**** "BBB@ HK.\2:E)HWA[5-0
MB57EM;66=%?[I*H6 ..W%?G/\ _^"G/Q#^*_QD\(>$-3\,^&;2PUG4(K.::T
MBN!*BL<$KNF(S]0:!V/TIHHHH$%%%% !1110 45E^*/#]MXJ\/:AI-VH:"[A
M:)L]LC@_@<&OC_X"^([GX2_&6\\-:FYCMKJ5K*4$C D!^1L_IQZBO4PN!^MT
M:DX2]Z"O:VZ];_H?*9MGO]D8S#4*U+]W6?+SW^&71-6Z][KKV/M2BBBO+/JP
MHHHH **^,_VGO%ES\0_BE8>$](/VA+!Q:(D9R'N9" _Y?*OMM:OJ_P #^%+;
MP/X2TO0K4[HK*!8R^W'F-U9R/5F)/XUZF)P/U6A3JSE[T];6V7>]_P!#Y3+,
M]_M7,,3A*-+]W1=N>^\NJ2MTUUN]EW-VBOCWXD> ?BI?_&ZXO-/BU*19+KS-
M/OX9#]GAAS\H+?=3 ZJ<9YX.>?K^$.(D$A#2!1N(& 3WJ,7A(X:%.4:BES*^
MG0WRG-ZN9UL12J8>5)4I63EM+?5:+MYZ-:CZ***\X^D"BBB@ HHHH 3K7YV?
MMF? G_A7'C#_ (2;2+;9X=UJ4LR(/EMKD\LGL&Y8?\"'  K]%*YSXA^!--^)
M7@_4O#NK1[[2]B*;A]Z-NJNOH0<$?2N_!8IX6JI]'N>!G>5QS7".E]M:Q?G_
M )/9_P# /Q_Z5[;\(OVLO&7PMMQILTY\0:#M*"QOG):$'_GE)R5^AROM7FOQ
M$\!ZG\-/&&I>'=6CV7=G(5#@$+*G\+K[$<_IVKG*^]G3I8B%I*Z9^"4:^)RZ
MLW2DX36C_P F=B^LQ:S>7%R&Q)+(TC(W4$DFG5QJL5(()!'0BM2SUQX\+.-Z
M_P!X=1_C76I=#SVFW<[BPG,\ W$EEX)-60"Q  R3T K$T6]CED_=N&5O3UKL
M?"6FG5O$=A; E0TH)8=@.:]:G47LN9]#XC%X67USV45\35OG_P $^_?@]X>@
M\#_#'0[*79;-Y EF+L "[<D\_6MJ_P#'_A_3F*RZG"[>D.9/_00:^?9KB6X(
M,LKRD# +L6('XU'7YK/ JK4E4J2NV[G]/T<Y>$P\,/AZ:48))7UV5NECV.^^
M-&F0EA:V5S<D="^(U/\ ,_I3_!_Q,N?$^N"R?3UBA92P>-BQ3'K[5YSX3\&7
MWBNYQ"IBM5/[RX<?*/8>I]J]P\.^&+'PQ9B"SCP3]^5N7<^I/]*Y,3##4(N$
M5>7Y'K8"KF&-FJLY<L%Y+7R1K4445XY]8%%%% ')_%KQ$WA'X7>+M<0X?3M)
MNKI3[I$S?TK^>C0M U'Q1J::?I=K)>WLBLR0Q\LP52QQZ\ U^Z7[;GBM/!O[
M*OQ(OGQ^_P!+?3UZ_>N"(%Z>\@K\O?\ @FUHW]L_M:^%@T/FPP6]Y+)D9 'V
M>0<_B0/QH+6QUO\ P3#^/)^&GQG;PAJ-R4T/Q6%MU#N D=VO^J;GUR4ZC[^>
MU?L-7X9_MF?!BZ_9M_:*U"/2E>UTJ[F&KZ/,H"A%9MQ1<8 V/E0.R[?6OUV_
M9?\ C1!\>_@IX=\6*X:_EA%OJ"  ;+I !)P.!GA@!V84"?<]6K\S/^"LOQV,
M]WHOPMTVX.R(+J.J!<8)_P"62'Z<M^5?HA\1?'&G?#7P/K?B?591#8:7:R7,
MC$$_=&0,#GDX%?AGX<TG7_VN_P!I54=9);_Q+JAGN7521!!GYB<= J #/M0"
M/+-6\/:CH4-A+?VDEK'?P"ZMC(,>;$20''L<&OW"_8+U9=6_90\ %7#_ &:S
M-L<'H58\?K7P7_P5+^'-C\/O&_P^M]*MDM]-30A9Q+&FU0(F"C@#&3U_$U]6
M_P#!*[Q"=5_9G%@S%WT[5)X^2> Q# 4#>J/L>BBO@;]OG]O?4/A5JD_P\^'=
MS%%XB$>-3U@*'-EN'^KB!&/,QR6YV]L'H$[GV_XB\:^'?!Z(^O:]IFB(_*MJ
M-Y';AOIO89JMX>^)'A+Q=<&#0O%.BZU..3%I^H0SM^2,37X9^!_V??C1^TO/
M=>(-%\/:QXM,KD2ZQJ%RJ)*W<>?.ZAB/8G%7?'G['OQO^"FFGQ'K7@S4=,LK
M)A*=2TZZAN?L^#PY:"1C& ?XCC''- ['[Q45^8W[!7_!0'7)_%&D_#;XEZB^
MK6E^ZVNE:]=,6N8IC@)#,W616/ <_,&(!)!ROZ<T":L87CO_ )$CQ!_V#[C_
M -%M7X8?L9?\G3?#+_L-V_\ Z%7T'^V/^QA\9?'7[0'C_P 9:'X-:^\-74RW
M,-\-2LX]T:0(&;8\P<8*MP5SQ7Q=X-\':Q\0/%.F>'- L_[0UG4IUMK2V$B1
M^9(QP%W.0H^I(%!21_1U17Y;_L._L9_&/X0_M*>&?%/B[P<VD:#9Q7BSW9U*
MSFV%[:1$^6.9F.68#@=Z_42XN([2WEGF<1PQJ7=VZ* ,DF@EDE<GJ_Q;\#>'
M[U[/5/&?A[3;M#AH+S58(I ?=6<&ORH_;,_X*!>)OBOXBU+PMX%U.?0/!%K*
MT'VFQD,=QJ>#@NSC!6,\X0'D<MG.!XW\/?V,?C7\5]$CUOP[X#OKO39QOBN[
MNX@LUF']Y//D0L/<9% [=S]VM(UO3O$%DEYI=_:ZE:/]VXLYEEC;Z,I(J[7X
M16UI\</V(_&=EJ<]CJ_@VZ9PVR1A)97H'5&*,T4H]LDCVK@?C;\2F^,/Q4\1
M>,WM!8R:Q.MP]NIR$;8H8#VR#CVH#E/Z&Z^3OVP? LNF:SIOC*P5D\PK#<2)
MQLD7E&_'^E>_?!C_ )))X-_[!-M_Z+6KWQ'\'0>/?!>J:+,JDW$1\IF&=D@Y
M4CTY[^YKT\MQ7U/$QJ/;9^C/E>)<I6<Y95PR^/>/^):K[]OF9OP;\=Q_$/X?
MZ9JNY?M/EB&Y1<_+(O!Z_G7;U\??LI>,I_!WCO4?!VI%H4O&8(DAV[)TX(P?
M4#]*^P:O-,+]4Q,H1^%ZKT9CPKFSS?*Z=:?\2/NS_P 2_P ]'\PKE_B9XSA^
M'_@?5M<E(WV\)$*$CYY6X0>_)&?8&NHKY*_;"\<OK&OZ9X-L"91;%9[B-!RT
MSC"+]0I[?WZC+<+]<Q,:;VW?HOZL:\39M_8V5U<3'XW[L?\ $]%]V_R*?[)7
M@J;Q9XWU+QEJ69TL681R2Y)DN9,DMGN54G.>[@U]@UQGP@\"1_#KX?Z5HX4?
M:5C\VZ8'.Z9N7Y[@'@>P%=G59GB_KF*E-?"M%Z+^KF?"V4_V/E=.A-?O)>]/
M_$]_NT7R"BOCWXH_\G=:1_U^Z?\ ^R5]A5GB\']5A2GS7YXWVV.G*,X_M2MB
MJ7L^7V,W#>][==E;TU]0I"0H))  ZDUF^)?$5CX3T.\U;4IA!9VL9DD<^W8>
MI/0"OC[5/%'C[]I[Q-/INC>98:!&3F'>8X(T/0S,/OL?3GV'>KP6 GBU*;DH
MPCO)_P!;F&=\04LG<*$*;JUZGPPCN_-]EY_Y,^N)?'7AN"8PR>(=*CF!P8WO
M8PP/IC=6Q!/'<Q++#(DL3#*NC!E(]B*^9+/]B*U^QK]K\5S?:RO)ALQL4_BV
M2/RKF-2\$?$3]F2\&L:1J']L>'0_[Y8]WE%?^FL1SM)_O G'K7<LOP==\F&Q
M%Y]$TU?T9X4N(LYP*]OF>7.-'JX34G%=W%=%UV/L:BOARW\96OC[]HS0-<M%
M:..ZN("T;=4;;ROYU]QUPX[ RP/(I.[DK[6MY'O9#GU//E7E2A:-.7*G>_,M
MT]E:_;4****\L^J/G+]LCX#_ /"RO"'_  D6CVOF>)-(C+;8DR]U;]6CX&21
MR5'U'>OSIZ5^T3*&!! (/!!K\YOVQO@4?AIXR/B#2K?9X=UB0N%0?+;W!Y9.
MF #U'XCL*^JRC&?\P\WZ?Y'Y7Q?D_P#S,:*\I?H_T?R/G:BBOICQGKWP1F_9
MRL;31;.W3QIY4:_\>S"\$X_UA>3&"G7'.,8 YKZ&K5=-Q2BW=VTZ>I^=87"K
M$QJ2=2,>57U=K^2\SYQTZ^>PNDE4\ \CU%?1WP1L!?:A/J6,QQQ!5/NW_P!:
MOF>OK[X$:*]CX TX^4?M%W^\( Y(_AK:I5]G1E'N<N$P2Q.-I56O@N_\OQ._
MKO?!'PRGUO9>:D&M['JL?1Y?\![U3T'PP+5DN+H!IARL?9?KZFO1=,\820A8
M[M/-3IO7AA^'>ODL3B)VY:/]>A^Q9=@:3DIXK;HO\SJK.S@T^VCM[:)884&%
M1!@"IJKV>H6^H1[X)5D'<#J/J*L5\X[WU/OX\MER[!1112*"BBB@#Y%_X*D:
MW'I?[*6HVCMAM2U.SMD'J5D\W^41KY4_X)$Z)'>?&[Q5J4D8<V>A,L;$?==Y
MXAD?\!##\:]A_P""P6NF#X:^ M&W8%UJ\MWMSU\J$K_[6K"_X([^'MNG_$C7
M'7[TEG9Q-[8E9Q_Z!05T/:O^"DOP"'Q=^!TVO:=;>;XB\+%KZ#RXP9)8,?OH
M\]<8 ; ZE!7R=_P2L^/!\&?$R^^'NI7 32O$:A[3?_!>(/E .>-RY&,<G;Z5
M^L=U:Q7MM+;SQK+#*A1T89#*1@@U^&'[4'PMU']E;]I6\BTC?96D-VNKZ+/$
M"@6(MN55.?X""O7H!ZT M=#Z_P#^"L?QY73M#T?X7:7<K]IOB+_50C'<D2G]
MTA'^TV3U_A/%2_\ !)_X"_V5X?U;XH:I; 7-^38Z69%(98A_K)!G^\<#(ZC-
M?#,E[XK_ &P/VAK9KO$VN^)+Z.(JA(C@CX! Z[55037[K^ ?!>G?#KP7HOAG
M2HQ%I^EVJ6T2CN%'+'W)R3]: >BL? __  6$TE/^$:^'VI[/G%W/;;_;9NQ5
MW_@C_P"(HIO OCK1&;_2(;^*Z5?]ADV_S%>@?\%5/#D&K?LTKJ3KFXTS5('B
M.!P'RK?I7SG_ ,$@]6CMOB?XVL&D"R7.F1.B$\MMD.<?3- =#]/O&.N-X8\(
MZWK"H)6T^QGNPC=&*1LV#^5?S]V&J:?\0?C#%J7C35?L&EZGJOVC5+^19)"D
M3/NDX0%B<9 P,\BOWZ^(NE3Z]\/_ !-IMLADN;S3+FWB0?Q.T3*H_,BOY]_"
M?A*TUOXD:=X:UO4FT"VN=0%C<7WV?SC;$OLW%"RY .,_,.,F@<3]B?#G[>G[
M-/A/0-/T;2O'=O9:;80);V]O%HU^JQHHP  (..E7Y?\ @HA^SK/$\4GQ!ADC
M=2K(VCWY# ]01Y'2OFB/_@C?%+&KI\7RR, 0P\-\$?\ @72_\.;$_P"BNM_X
M37_W70+0^)/VCG\$0_&[Q%>?#'4EO/",]RMWI\UO#+;B$N [1JLBJP".64<=
M #7[C? 3QM+\2/@KX'\37'%UJFCVUS./25HUW_ANS7P;;_\ !'NSNY[F"#XS
M1S36KB.>./P\K-$Q4,%<"[RI*LIP>Q![U]]_!GX<#X1?"SPSX-&H?VJ-%LH[
M/[;Y/D^=M&-VS<VW/ID_6@&S7\=_\B1X@_[!]Q_Z+:OPP_8R_P"3IOAE_P!A
MNW_]"K]S_'?_ ")'B#_L'W'_ *+:OPP_8R_Y.F^&7_8;M_\ T*@$?O97S7_P
M4.^(%U\/_P!EKQ3)8L$N]3$>F*Q[)*P60CWV%L5]*5\H?\%-O#-YX@_96UJ:
MSA>=M.N[>\D1!DB,2 ,WT ))]A0)'P#_ ,$Z_@+IOQO^.B/KMLEYH.@6_P#:
M-Q;2?=G<,%C0C'(W$$CN :_:J*)((DCC18XT 5448"@= !V%?D3_ ,$I?B1I
MOA'XYZGH&HRI WB'3S;VDDC!09D<.$Y[L 0!U)Q7Z\T#EN<K\3_AKH7Q=\$:
MIX5\1V4=[IE_$4977)C;^%U]&4\@BOY__BEX&G^&?Q%\1>%KEF>72KV2VWN,
M%E!^4D>I&#^-?T1:AJ%OI5A<7MW,MO:V\;2RRN<*BJ,DG\!7\^_[0WCN#XF?
M&[QIXGM6#VNHZE))"Z]&0?*K#ZA0?QH")^[OP8_Y))X-_P"P3;?^BUKLZXSX
M,?\ ))/!O_8)MO\ T6M=G02?'/[4?A6X\ _$G3O%^E@0K>N)PPZ"X0@G(]^#
M^-?4_@/Q9;^-_".F:U;'*7<*NP/56_B!]P<UA_&SP(/B%\.]3TU$W7:+]HM<
M=?,4$@?B,C\:\2_8[\>/:W6I^#;YMC FYM5<G(8'$B>GH<>YKZB?^WY:I_;I
M:/\ P_U^3/RJA_QCW$TJ&U'&*Z[*HMU\_P!4?2?BKQ%:^$O#FHZQ>NJ6UG"T
MK;FQN('"@^I. /<U\@_L]^&[GXL?&.\\4:J#+;V4IOY2R[E:9B?+7GICEO;8
M*[K]LGX@?9-,T_PG:RD27)%U=A3_   X13]3DX]A7I?[._P^'P_^&]C%-&$U
M&^_TNZ/.0S#Y5.?[JX'U!IT/]@RV5;[=71>G7^O06._XR'B6E@EK1POOR[.;
MV7RT^Z2/3J***^6/U8^/?BC_ ,G=:1_U^Z?_ "2OL*OCWXH_\G=:1_U^Z?\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>mtva-20260608xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 mtva-20260608xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "# JT# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=VU?WA11161UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ>DZO9:[I\%]IUW#?6<ZAXKBW<.CJ>A!'!%7*\)JVC/O4U)71\Y_MR:BMO\
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M^:\'X#^T<[P]-KW8OF?I'7\79?,^EZ***_(C^Q0HHHH **** "BBB@ HHHH
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M"7VF>7[L40/8NY51_O5_/MXK\3ZCXV\3ZMXAUBX^U:KJMW+>W<V N^61R[G
MX R3P.!04E<_=3X._MB?"OX\^*Y?#G@SQ!+J6KQVKWC02V$\ \I656(:1%!(
M+KQG/7T->U5^(O\ P3=U!K']L;P*@E,4=RE_"X#8#C[%.P4^OS*O'J!7[=4"
M:L%%%% @HHHH **** "BBB@ HHHH ***_._]K7_@HE\0?@+\>_$G@?0M$\/7
MFEZ:MJT4U_#,TS>9;12MN*RJ.KD#CIB@=KGZ(45\*?L/?MV>./VF/B]J'A7Q
M)I&A6%A;Z--J*RZ;#*DAD2:% "7D88Q*W;L*^ZZ!;!1110 4444 %%%% !11
M10 5D>*?%&G^#="N=7U1Y(K"V ,LD<32%02!G"@G&2*UZIZQI5MKNE7FG7D8
MFM+N)H94/\2L,$?D:N'+S+GVZF-95'2DJ+2G9VOM?I?RN>=:3^TM\/M:U2TT
M^UUEVN;J58(@]I*@+L< $E<#DCDUZC7YH>-_"MUX#\8ZGHERS">QG*+)T+KU
M1QZ94J?QK[S^"?CY?B-\.M+U1W#7R+]FO!W$R !C_P "&&^C5])FN5TL)2A7
MP[;A+O\ @?F?"7%6*S?%5\!F,8QJPV236SM):MZIV_I'>4445\P?J04444 %
M%%% %/6-6M=!TJ\U*^E$%E:1-/-*03M11DG Y/ [5YC'^U-\.975$UB=W8@*
MJV,Y)/I]RN-_;%^(/]D^&K/PK;28N=3837.#RL"'@?\  G _!#7C_P"RY\/O
M^$T^)$-[<1;].T8"[DR.&DS^Z7\P6_X :^IP>5T)8*6,Q3:6MK?\-U9^3YSQ
M5CJ>>4LFRN,6W92<DW9O5[-:1CJ_^ ?=2-O16 (!&<$8-97B;Q9I'@W3&U#6
MM0ATZT4[?,F;&X^BCJ3[#FM>OE3]M31=8GO- U%(Y9=%BB>)BF2L4Q;)+>FY
M<8/^R:\? 8:.,Q,:,Y63/M>(<SJY-EM3&T:?/*-M.FKM=VZ+<^@?!OQ1\+?$
M!I5T'6(+^6(9>$920#UV, <<CG&*ZJO@C]F;1M6O_B[HMSI\4H@M&>2ZF .Q
M(MC AC[YP/<U]["NC-<%3P%=4J<KIJ_FCS>$\]Q&?X!XG$4^22DUI>ST3NK^
MMNHM%%%>,?:A1110 4444 %%%% !1110 5X9^UA\"D^,'@5KK3H ?$VDJTUF
MRCYITZO 3[XR/1@.F37N=%;4JLJ,U4ANCDQ>%I8VA+#UE>,E_7W'XNO&T3LC
MJ4=3AE88(/H:;Q7U3^V[\!SX2\0?\)SHMMMT?5)=M_'&.+>Y/._'97Y/LP/]
MX"OE:OT3#UXXFFJD>I_.>88&KEV)EAJNZZ]UT9W?PN^-OB[X0:AY_AW5&CMF
M;=+I]Q^\MICQG<F>#P/F7#<=:^Y?@U^V9X2^))@T_667PQKKX417,@-O,W/W
M)>!GI\K8.3@9K\WZ*YL5@*.*UDK/NOZU/2RS/L9E;4:<N:'\KV^7;Y'V/^W3
M?^?\0] M@VZ.+2A*,'C+RR _^@"OFRL)_%6IW/V<7MW-?I;Q""(7$A<QQ@DA
M%)Z $G Z<UIV>HPW@^1L/W1NM=V$I>PHQI7V/+S/%_7\74Q5K<SV[:%JNE\!
M^/-7\ :I=7>C71LY[RU>RDE4?,L;D$E?0Y48/:N:HKK:C+22NCS%*<-:<G%]
MUNCI'9G8LQ+,QR23DDTVHK67S[='[XP?K4M>TG=71^;3BX2<9;H6OT7^"_A4
M^#/AAX>TMXS'<+;+-.K=1+)\[@_0L1^%?"?PI\+#QI\1= T=T62"XNE,ZL<
MPI\\@S_N*U?H?>^(]*TOY;F_MX& ^ZT@!_*OB.):SE[/#Q]7^2_4_=?#'!1A
M]8S&IIM!/\9?^VFG17%7WQ;T&U!\J2:[8=HHR/U;%<]??&QR2+/30!V:>3^@
M']:^-CA*\]HG[74S3!TMZB?IK^1ZM2%@O4@?6O"+[XI^(+W(6XCM5/:",?S.
M:Y^]US4=1)^U7UQ./1Y"1^72NN&75'\32/+J<04(_P .#?X'TK',DP)1U<#C
M*G-/KR#X,VE__:MS<*'73C$5<G[K/D8QZD<_Y->OUPUZ7L9N"=SVL%B7BZ*J
MN/+<****YSO"BBB@ HHHH BNKF*RMIKB>18H(D,CR,<!5 R2?8"OYO=9U%]7
MU>^OY/\ 674[SM]68D_SK^@7]HC5O["^ /Q)U#?Y;6_AO49$;_:%M)M_7%?S
MW4%Q"OU@_P""4?QY_P"$M^'.I_#74[C=J?AMC=:?O;YI+*1OF4?]<Y"?PE0#
MI7YN:S\&M>T7X->'/B5+$7T#6M1NM-C=5/[J2$*06.,?.?-"_P#7%ZT?V;/C
M/=_ 'XT>&_&<'FO:6<XCU"WBY,]H_P LR 9 )VDE<G&Y5/:@;U/Z!:*JZ5JE
MIKFF6>HV%Q'>6-W"EQ;W$+!DEC90RLI'4$$$'WJU09A117,?$WX@Z7\*OA_K
M_B[69!'INCV<EU+E@"Y4?+&N?XF;:H'<L!0!^=?_  5H^/?V_6-$^$^EW&8;
M+;JNL;&ZRLI$$)P>R,TA!'\<9[5^<]=#\0_'.I_$SQSKOBK69?.U/5[N2[G/
M8%FR%'HJC"@=@!6WJWPAU?1/@QH'Q%NT>+2];U6YTVS5HR XA12TF[T+%T'O
M$_I0:+0TOV7]3ET?]I'X774,IA(\3:<C,#CY'N41Q^*LP_&OZ!:_FVTK5+K0
M]4L]1L9FM[VSF2X@F3[T<B,&5A[@@&OZ1;:=;JWBF3E)$#K]",T"D24444$!
M116=KWB/2O"VF3ZCK.HVNE6$"EY;F\F6*-%'4EF( % &C17SCXJ_X*%_ ;PG
M?-:3>.8=0F49+:7:S7<?X21H5/YU1T;_ (*0_ /6;V*U'C&2S>1MJO>:=<Q1
M@^[F/:H]R10.Q].45S_@WX@^&?B)I@U'PQK^G:_8DD>?IURDR9'494GD5T%
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MUTG@CX80Z/Y=[J@2XO>JQ=4B/]3^E=^!BO#Q..O[E+[S[++LEM:KBEZ+_/\
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M_P B/X>_[!UO_P"BEK=K\OJ_Q)>K/ZJPO^[T_P#"OR"BBBLCJ"DI:* /@?\
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M!!)(KED2,@M\I/=L?A7V500]PK\1_P#@I+_R>1XY_P"N>G_^D,%?MQ7XC_\
M!27_ )/(\<_]<]/_ /2&"@<=SO?^"27_ "<QK7_8KW7_ *4VM?KW7Y"?\$DO
M^3F-:_[%>Z_]*;6OU[H"6X5\4?\ !67Q7=:)^S?IFDVTOEQZUKT$%RN/OPQQ
MRS8_[^1Q'\*^UZ^#O^"OMH[_  1\&W('[N/Q$(S]6MIB/_0#0);GY.@$D <D
MU_0=^SS\*[3X+_!CPGX1MH%@EL+&/[65Q^\NF&Z=R>^9"WX8':OY](9/*F1\
M9VL&P:_I \/ZY:>)M!TW6+"3S;'4+:.[MY/[T<BAE/Y$4%2-"BBB@@S/$WAO
M3O&/AW4]"U>V6\TO4K:2TNK=\XDB=2K+QSR">17\\?Q,\&O\.OB-XI\*23BZ
M?0]5NM--P%VB7R96CWX[9VYQ[U_1?7\^G[2FKVVO?M#_ !-U"SFCN+2X\2ZB
M\,T)RDB?:7VL#W!&#GOF@J)]1_\ !(7_ )+WXM_[%F3_ -*K>OUHK\E_^"0O
M_)>_%O\ V+,G_I5;U^M% GN%(:6B@1\5?M<?#W_A&O'$7B"UBV6.M*6DV@ +
M<+@/T_O#:WN2U=W^QI\0#=Z;J/A&ZDS):YN[,,?^6;'$BCZ,0?\ @9KU[XV^
M %^(_P .]3TM$#7R+]ILSZ3("0/^!#*_\"KX2^'WB^Y^'?CC2];B5M]E/^^B
MZ%XS\LB<]RI8>QK[_"-9MEDL._CAM\MO\C^>LXB^$N*:>8P5J-;5_/2:^3M+
M[C]*:2J^G:A;ZK86U[:RK/:W$:RQ2H<AT89!'U!KD/C/X^3X<?#S5-6#JMX4
M\BS4D9:=^%P.^.6(]%-?"TZ4ZM14HK5NQ^\XG%T<+AYXJH_<BG)OR2N?)G[4
MGQ!_X3/XCS6-O)OT[1@;2/!X,N?WK?\ ?0V_\ KV/]COX>_V/X6N_%-U$!=:
MHWE6Q(&5@0X)'<;G!X_V%-?+'@KPO=^/O&&FZ-;EFN+^<*TA&=J]7<_0 G\*
M_2/1]*MM"TJSTZSC\JTM(4@B3^ZJ@ #\A7VV=5(X+"4\!2Z[^B_S9^&\$X:I
MGF<8C/\ %+1-\O\ B?\ \C'3YHN4445\(?OP5X3^V/\ \DJMO^PI#_Z+DKW:
MO"?VQ_\ DE5M_P!A2'_T7)7J97_OU+U/E.*_^1'B_P# SS;]B;_D;O$7_7BG
M_HP5]?U\@?L3?\C=XB_Z\4_]&"OK^NW/_P#?Y^B_(\/P^_Y$%+UE_P"E,0U^
M>/QZUQ]?^+_B>=F++%=M:J#V$7[O _%2?QK]#C7YO_%JSDL?BCXLAD&&_M2Y
M8?1I&8'\B*]#AE)XBHWO;]3Y_P 4)S67X>"^%SU^2=OS9]Z?"GPJG@OX=Z!I
M*QB.6"U0S@'.96&Z0_\ ?1:NMK/\/ZG!K6A:=J%LV^WN[>.>-AW5E##]#6A7
MR=64IU)2GNV[GZYA*=.CAZ=.C\*BDO1+0****R.L@OK*#4K*>TNHEGMIXVBE
MB<95U88((]"#7YG>+-$/AGQ3K&D%_-^P7DUKOQC=L<KG\<5^G%?FW\5;A+KX
MG>+98V#QOJUT58="/-;FOM>&92]I4CTLC\/\4:5-X;#57\2E)?)I7_%(_0?P
M)_R(_A[_ +!UO_Z*6MVL+P)_R(_A[_L'6_\ Z*6MVOCZO\27JS]FPO\ N]/_
M  K\@HHHK(Z@HHHH *\2_:J^!B?&+P&\UA"#XETH-/8L.#*/XX3_ +P''^T!
MT!->VTE:TJLJ,U4ANCDQ>%IXRA+#UE>,E;^O0_%Z2-X9'CD4HZ$JRL,$$=0:
M;FOLK]KW]EJ_EUB^\=>$;,W4-Q^^U/3X1F1)/XID7N#U8=0<GH3CXV92C%6!
M5AP0>HK]#PV)AB::G#_AC^=\RRZMEF(="LO1]&NZ/3_!/[2WQ!^'WAG^P=&U
MPQ:<H(A26)9&@SR=A(X'L<BO-;R]GU&\GN[J9[BYGD:66:1MS.[')8D]22<U
M#^='YUM&E"#<HQ2;W..KB:]:$:=2;:CLF]O0,U]/_LT>&9--\)7&IRQD2ZE-
M^['<QIP#^+;OTKQOX4?"C5/B;KL4%O#(NGHP-Q<XX5?0'U-?>_A?P?9^&K&W
M@BC7,$:QQ@#Y8U P /\ &N+&8B-*/+U9[^2Y;4Q-3VS5HKJ5=#\*_=GO5]UA
M_P ?\*ZA5"* H  X ':EHKYR<Y3=V?I=&C"A'E@@IT<C1.'1BC#HRG!%-HK,
MZ#H--\73V^$N5\Y/[PX8?XUU%CJEMJ*;H90Q[J>"/PKS>G1R/$X9&*,.A4X-
M<\Z$9;:'=2QDX:2U1ZC17&Z;XOF@PETOG)_?'##_ !KK;:YCNX$FB;<CC(-<
M,Z<H;GL4J\*WPLEHHHK,W"BBB@ HHHH _%#_ (*7>))M?_:\\56TC[H=)MK*
MP@]E^S)*P_[[F>JW_!-S15UC]L#P6[J'CLH[VZ8$9Y%K*JG\&93^%<!^UQXD
MD\6?M.?$[4)&W8UZZM4/^Q#(84_\=C6OHC_@D;H8O?V@/$FINH9;'P[*BDC[
MKR7$(!_[Y5Q^-!IT/UOHHHH,SQ_]K'X'0?M!_ WQ#X5V(=4\O[9I4K_\L[R,
M$Q\]@V60GT<U^"5Y9SZ?=SVMS$\%S [12Q2##(ZG!4CL0017])M?$7QM_P""
M7?AOXN_%#7O&-GXPN/#2ZQ-]IETZ#35F1)2H\QPWF+]]LL1CJQH*3L?E!X0\
M*ZEXY\4Z3X>T>W-UJFJ74=G;0K_%([!5^@R>M?T#_!CX7Z=\%_A;X:\%:7AK
M72+18&E QYTIRTLI&3@O(SMCMNQ7SC^S7_P3A\/?L]?%"V\:R>*9_%%W9V\L
M=I;SV"P+#*XV^;D2-DA2X Q_%G/%?8= -W"BBB@D_G\_:C\/-X5_:/\ B9II
M3RUC\0WLD:^D;S,Z?^.LM?3_ /P2%U\VGQO\7Z.3A+[0#<#W:*XB 'Y2M^5>
M4_\ !1[P])H'[7_C5S$8X-06SO823]X-:Q*Q_P"_B2#\*N_\$S=>&C?M>>%[
M<Y"ZG:7UF3NP!_H[RC/KS$!]2*"^A^UM>6_M/_"MOC5\!/&GA"%!)?7UBSV2
MEMN;F(B6$$]@9$4'V)KU*B@@_FOG@DMII(9D:*6-BCHXP58'!!'8U^MO_!,G
M]IW3?''PQM/AGK-ZD'BCPZACLDF?!O++.4V9ZM'G81_="'UKQ;_@H_\ L77V
MA>(]0^*W@K3I+K1M0=KC7;. ;FM;@G+7 7KY;DY;KM;)X# #X#TK5K[0M1M[
M_3;RXT^_MW$D-S:RM'+&PZ%64@@^XH--T?TD45^-7@#_ (*B?&7P?96]GJ4N
ME>*8(LYFU&V*W##L-\94<>NVNA\3_P#!6CXIZI#Y>CZ'H&C94@R/')<.#ZKE
ME _$&@FS/TS^-_QO\,? +P'?>)_$]ZD,,*$6]HK#SKN7!VQ1KW8D?0#). #7
M@/P!_P""EOPW^+)M]-\2O_P@WB&3"^5?R VDK'^Y/P/3A@I],U^3/Q+^+?C#
MXPZZ=8\8Z_>:[? 81KA@$B''"(,*@X'W0,]Z]:_8\_9"UW]IKQI"\T,^G^"+
M&4'4]5VX# 8)AB)X,C#_ +Y!R>P(.W<_<>">.YACFAD66*10R.AR&!Y!!]*D
MJEHNC67AW1['2M-MH[/3K&!+:VMXAA(HT4*J@>@  J[00%?B/_P4E_Y/(\<_
M]<]/_P#2&"OVXK\1_P#@I+_R>1XY_P"N>G_^D,%!4=SO?^"27_)S&M?]BO=?
M^E-K7Z]U^0G_  22_P"3F-:_[%>Z_P#2FUK]>Z EN%>!_MS?".;XR_LT>+-(
ML;<7.L6,:ZMIZ!"[M+ =Y5 .2SQ^8@]WKWRB@D_FLZ5^KO\ P30_:UTWQ5X(
ML?A5XFU!+;Q)HZ&+2'N'Q]NM!DK&I)Y>,9&W^X%QG:V/G;_@H3^QE>_"'Q=>
M^/?"=B\W@?5IC-<16\?&EW#G+(0.!$Q.5/09V]@3\8VEY/I]U#=6L\EM<PN)
M(IH7*/&P.0RD<@@\@B@TW1_2;17XN?#C_@IE\9_ .EV^G75[IWBBUAPJR:Q;
MEI]H& OF(RY^K GU)K2\;_\ !4KXR^*;">STTZ/X:24 "XL+4O<)ZX9V*_\
MCM!/*S[L_;H_:[TS]GSX>WNCZ/?1R^/]7@:&PMXF#-9JP*FY<<XV\[0?O,!V
M!Q^*-=-I]CXI^,?CN"UA^W>)O%&L7"QJ9':::>1N!ECS@>IX 'H*M_%_X<7/
MPB^).N>#KRZCO+S1Y5MIYX00C2;%+[<\[=Q(!."0!P.E!25CZZ_X)"_\E[\6
M_P#8LR?^E5O7ZT5^2_\ P2%_Y+WXM_[%F3_TJMZ_6B@A[A1110(0U\)?M/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>mtva-20260608.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2026 7:16:26 PM-->
<!--Modified on: 6/2/2026 7:16:26 PM-->
<xsd:schema targetNamespace="http://metaviatx.com/20260608" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:mtva="http://metaviatx.com/20260608">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20260608_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="mtva-20260608_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>mtva-20260608_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2026 7:16:26 PM-->
<!--Modified on: 6/2/2026 7:16:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>mtva-20260608_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.3.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 6/2/2026 7:16:26 PM-->
<!--Modified on: 6/2/2026 7:16:26 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="mtva-20260608.xsd#DocumentDocumentAndEntityInformation" roleURI="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://metaviatx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_639160245864017720" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_639160245864017720" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_639160245864017720" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_639160245864017720" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_639160245864017720" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_639160245864017720" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_639160245864017720" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_639160245864017720" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_639160245864017720" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_639160245864017720" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_639160245864017720" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_639160245864017720" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_639160245864017720" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_639160245864017720" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_639160245864017720" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_639160245864017720" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_639160245864017720" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_639160245864017720" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_639160245864017720" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_639160245864017720" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_639160245864017720" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_639160245864017720" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_639160245864017720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_639160245864017720" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jun. 08, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun.  08,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">METAVIA INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2389984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">545 Concord Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">702-9600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MTVA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001638287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="mtva-20260608x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metaviatx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mtva-20260608.xsd</File>
    <File>mtva-20260608_lab.xml</File>
    <File>mtva-20260608_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="mtva-20260608x8k.htm">mtva-20260608x8k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mtva-20260608x8k001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "mtva-20260608x8k.htm": {
   "nsprefix": "mtva",
   "nsuri": "http://metaviatx.com/20260608",
   "dts": {
    "schema": {
     "local": [
      "mtva-20260608.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mtva-20260608_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mtva-20260608_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "mtva-20260608x8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://metaviatx.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20260608x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "mtva-20260608x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://metaviatx.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001104659-26-071211-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-26-071211-xbrl.zip
M4$L#!!0    ( #9HR%P[72?E! ,  &P*   1    ;71V82TR,#(V,#8P."YX
M<V2U55MOTS 4?I_$?S!Y3YRDK*Q1VXDQD)!60&-(>T-N<MI:.':PG;;[]]AN
MW'O33H*G.#[?^<[]N'^[+!F:@U14\$&01'& @.>BH'PZ"&H]"6^"V^&;J_[;
M,'R^>WQ A<CK$KA&N02BH4 +JF?H2505X6@$4E+&T)VDQ1002I*H$\51@L)P
MZ"CNB#(J@B/'E4:)%WQLV 3/4!>G.(W3+GJ?)=W,?+^//&QD')O0,[BE*C*5
MSZ D2!,Y!?V5E* JDL,@F&E=91B7H,F<$KV,<E$ZDK@;WP2(:"WIN-;P6<CR
M'B:D9MJD@?^I"7.&3788V/AW %MBDTZN,N/"VM9BL8@6G4C(J3$4)_AY]/##
M>>?!!= U>#F6+%*01U,QQT9@?;OV0 F3'58';GB[V$C7YHV@T+ND#>X:KX1K
M*#M)V<'/#Y3_]LA:RY/0'C92#V1&J874BL>F#S8>[..;;"6]7@\[J8=RF-HN
M:7%#"@:X@7FM"XKJJT;/5RVD7&G"<]A.-FV)=Q]?:!GJEPK4<1TCQE9L*_\N
MC).PDWA-X'69'JMJ&F-8:N"*CAF$%@:2:#/1*DSM1/L^JR3DER1P@]QD7I_/
MNMX*L05=;%K%]2(]VJC=5:-2#RWUG)R;W^$50F[\">="NPS8*W]9591/Q.K&
MW-G.RJSK3R;=R!Y^/GXY8<)%>-_L/O_]P(M/7%/]\L70RM+9"Q UZ;T(Z1WQ
MKA0PH9PZIV.3IQB%R.MO'PDOT(H,;;'U\3[''GMM-N\W/G1G4UUEJ)RB'?%&
MN8&T*.:$Y35[O=[&K9-JS:6OQVZ5_,YXA ER&R&S(S((%"TK9B?+W<W<@K2-
M$OJ6^&5"C4P#>8BE;YE55^;][#2&/061^0'+P<8R)*("J2FHK86'_U54C(Q?
M&Y51 ?9?PNGCO>EJ+G9FT$V@B4M(C?C!>]RV-5=/^8/('5>+BOU;;^?07H5)
M:M9G9$PWSK9[<?R=O-"^5["&KU]G\O"]/V93G8+;@VV-RZV>?W!..7!.T_VK
MM2.K3EB1#?\"4$L#!!0    ( #9HR%R*%K&/@04  #(^   5    ;71V82TR
M,#(V,#8P.%]L86(N>&ULU9OA;^(V&,:_G[3_X1W[LDD7TJ2Z;D5M3RW7FZK1
M*SJ8=MHTG4)BP%JPD6,*_/>SDYB28 <*)3)?KBGOX\?/:WYU$LA=?5Q,8GA&
M+,&47#>\YED#$ EIA,GHNC'C0^>WQL>;']Y=_>@XW^Z^=B"BX6R""(>0H8"C
M".:8CZ%/I]. P"-B#,<QW#$<C1" YS7/FV=-#QSG)K6X"Q(QA!)(O?RFIPKM
MW(V2%ERXONN?^1?P:\N[:(F?W4<E>Q3!AGB++L;DOY;\9R!F ]$?25J+!%\W
MQIQ/6ZX[G\^;\_,F92,Q_,QSOSUV>N$830('DX0')$0-$/I6DK[8H6' T\59
M&[X8L%@9G+NKN8P*^9NC9(Y\R?%\Y]QK+I*HD4>4Y1TF47)9C?AJP+KX@YL5
M5](-Z[Q][_+RTDVKC9MW /G*!0,4=\01I)467T[1=0,M."(1DFG35QF-445:
M6797QM*:A@6_6"XK9<INS- PLTM4,PD*FR/Z[$8(R[?Y@SQPY(%<M)_$+]_;
M5(![.T@X"T*NG-+XUPU=72[&3BOLJM#2ZY85DP<L5'.)PRWKD"O<D JLIMQ)
M'=7P(:,3?=)L.JHI?H\'\=ZM%/I@**$SEL*^^SNZ'M^TTJN(0B%W$42</WNO
MR'SS2>TQ 8G@GG#,E_! AI1-TK]$^$?-].]5ENB(C*DL?>&H:;Q4MI<P71\*
ML/6:G7QI$QZ,EW2KCZ N8IA&]R3Z),YT%3V6=?8SI>VL#%=!9#=E^J@'XY;9
MB@TM FE\?/*RK?,SCM&7V62 F*9EC<1>WDS]*-3*=3LI,Z;<%[#\#"D=(;.L
M"ZVO:(3EF9CP+\%$MZ<99+8CIN^KB%E18S-JAJ0'XO;B"M*V+N0>Q,TIFU*6
M7@GVN-A'VW1&.%NV:60F<-LHVX'<J>LBGY5#;,9UM^ 'TEN8Y#VDTP!ED$\%
M<JZZD.X'BX=(7"#@(<X^:MARMC;K;<=X2Z=%@ UBF]'=%OE :(4]%/UK/M_?
M1I%8M"3_T<$$><:UT&MM)[2BPR*=&J'-9%;%/9#*W/.].@#I#D^DMOUSLS?_
M%>O@GR25_JY4^J=%I7\$*E^@[,]IS5"VQ>$3Z],YV;8(!>6) +G9G1;'%]D)
MP*@)^U8H2FMYD2G-:^8PO<!]8EU&GS$)S3=*1OF)$&GH4XME27L";)H2OQ6@
MJ]L@-4/-E'9IPH/X;SRMO)DWB$^$4&V/6CX+RA.@4Y_WK=C,W$'8UW1S+G?K
M6X8" XNELKWTZ?I8?;6\5K.3,&W"?9E*3\#2K2:$Y+,C<7=,B?D+&(W$7I1,
M_2B<RG4[D3*FW!>KU!!2Q]H^D/F+8<X1:=/)9$;R3X,23;,FG;V057:F2-.*
M[,2M.NJ^S.6N4+0]/G<]&N,0<TQ&C^):D>% U[)69"]QYIX4;IL*.UFKR+DO
M:"^6H#R/3UF7(0DV$F];^MB/?/20/0V'VE-HI=A>ZK;WJ.@S*^VD<(>\^](H
MK)UPS1LR<TC=:^?R(4EFB+V*3MV0DV'4V*^!U W]2?!J3OUFU&93U QO#X4S
M<=6P]/Q!'_-8=U.KD=@+IZF?U4F[5+<3/F/*?6%+78 .P?-_'OP"RO_X?/59
M(/_;2&\Y&5!=I^6ZO61I.U%8%8IV,J6/N#=0F1MD=O7M4_>+<"P2(\.SA0:9
MO515]57>L]8U=C)6F73OFXW<%)1KK<\6WD\0&PG2?V=TSL?BDF :D*7Q4V^3
MVEX =^BR^$6$5FHGCKL$/O"K"&4.F3OD]G71V187CBR('\0EX^(/9.9R4V<[
MD8;.BBR61#93:(IZ('^Y+:2^((R/3]ZMN%N)Y!W+YS@8:?HMU^TE3=N)(JQ0
MM),L?<1]B5JY@;1;X^C*?9FX(XYNWJE7\K$W_P-02P,$%     @ -FC(7(1V
MVU=R!   02<  !4   !M='9A+3(P,C8P-C X7W!R92YX;6S56EV/XC84?1^I
M_\%-G_/)##,@8,6PLQ7JL(,&JJ[ZLC*) :N)'3GFZ]_7#O$LA 1"U8;ZA83X
M^/K<<XSCF]#YM(U"L$8LP91T#==R#("(3P-,%EUCQ>?FD_&I]]-=YV?3_/;\
M_@H"ZJ\B1#CP&8(<!6"#^1),:1Q# D:(,1R&X)GA8($ <%VK83F6"TRSEX9X
MAHGH0@E(8WF6JQH&631*VJ!I>[;G>$WPV':;;7$<CQ1L)(C-\05<B,E?;?DQ
M$Z,!D1])VML$=XTEYW';MC>;C;5I6)0M1'?'M;^-7B?^$D70Q"3AD/C(  +?
M3M*+K]2'/!7GH/MVQD(5H&%_C%6*D-],!3/E)=/US(9K;9/ R"C*Y@J#*+AL
MQ6?P![GL\2?Q,PW<5JMEIZU&[PZ #J,A>D=SD%YJ\UV,ND:"HSB4H=)K2X;F
M72/B:VA*_9VF\R03^>5S-C?4L4^"%\(QWPW)G+(HE=$ ,O[O[\,/*A'B<(TA
MWUH^C6S9:E<+E.9523$[32QF*!'!TMZOHBW+1H[X+Y Y4 MM.2(!"CZN8BZ'
M<!RGY0 3J$"'IY $8!\5_+,<988BQY#Z1U1".7LI.W9.1DM$N#14@GQK0==V
M@+#\-3W($VGK0VJI^/)]0,7ZT)\EG$&?JT@AG*&P:^3:[/^0AM)J*B+F6.2;
MOS<;+;?I>/</3\U[QWU\])P?W ZG09\=\X3,5Z'%Z=',.-4^0]@Q9"*>Z2]Q
M^&'YG-'H1)UL)%J1,&4!8F)--L J$3QH+!G#L!Z5QXAA*B9Z\%FLRV?D/L)I
MI?MEYID!7JT&[%>!+SA$7U?1#+$"[?,0+62O1#I3O'$#Q=_1 DOFA'^%4=&,
M+X)II'P%XIGZ]S=0?RCVG"RF+!5K(C1# [HBG.T&-"@WXVPOC;RY/H_,JH<;
M6#6%VV$@<A4;\?W.^,(Z58+7R)YK,LB,:=[ F'X0"-F2["!VN,@M-:4 JY$A
M5=EG9CS^+\SPKC##T]J,8O:9&4^W,V,@3M_8E&[()2M^(/4SX@+WS(;6[6Q(
M;W!O;,SH&N\?4)SU(@?7SY J":A:S[F=+6.:<!C^B>.S6ZXBL'Z67*:O#*FW
M^I:_W3Y#L,2"PV8M1+](6,E<;XTMG^F&XR4EY35V'J*%W)5(*\GK+;+_8)AS
M1 8TBE8DVT8G!;H7XK00OSISY4"]A?:$AMC'')/%2-R/&);CG<A_"M)"^XJT
ME?#UELUCAN2D0.+>GS[OE>\&V-M\7KCNE(.U,.)*^LJ0>LOE',EADJP0N\J6
MDRXZFE,M"651O47T!/DKL9[N7&\VE6_/BI:J'$0+"RJ15I+76RI/&91O_2>[
M:$:+;@U'[5J(?9FQ4KK>:EA-@I>MOX1D@4I>.!3!M-"],G'U@NT65>]+A-A"
MS(Y?&=WPI5@78TAVI65O(5H+,Z[EKSRIM_#=LQR(!!D,A^*.M/T-E;N1PVGD
M0Q7FRH%Z:^*^V!($<EOP)82+ N6/VK50_#)CI71)*=RQ\W\9ZMUU[+TP>/^_
MF][?4$L#!!0    ( #9HR%PO,F6LXQT  &S+   4    ;71V82TR,#(V,#8P
M.'@X:RYH=&WM?6M7VSJPZ/?S*W39=^_"6MC8SLL.;<\*(4!:7B6AKR]9LBTG
M+K85_"!)?_V9D>W$@5"@A0"%KKV!Q+(TFO>,1M+;_QW['KE@8>3RX-T;55;>
M$!98W':#_KLWC4ZSW7[SO^__Y^W_DR3B?MTZV2<VMQ*?!3&Q0D9C9I.1&P_J
MI,N'0QJ0 Q:&KN>1K="U^RQ[157EDJS(*I&DK*LM&L&;/*CG+8H/FUG'^+BZ
MH6UHBE8EM;I:K6L:.3Z8-4S?W7?-D(:3?!)UZ$R1C4I5E6O&Y;8=%EZX%B,?
MN$G:VW6B9/^D!3_R?VD?@QCP!+@*HKK-W'<K@S@>UC<VQF;HR1&SY#Z_V( '
M"&QE)6TX;30:C>112>9A?T,U#&-CC)UEC>J>&YS-M11=8EM-44H;^-@$;.7-
MQU?:S_6,3Z=-H2,[G@<UZ[>RD3Z<-ET(+#14-[X>['>L ?.IY 913 -K"HH[
MCB68^MR;.2K< "!AB/.-.*1!Y/#0IS&0!SI5*Y*B2R6UT,]B!/RJ$TV3%$U2
MJWDG?GQ!I[WX+*87+HW'LL5]P3]*5=%GXUV';[54&#-O'C+G6OI4-^!I$=_N
M+T@YQ=_[MP-&[?=O$4R"S25VGK@7[U8L'L0@6E(\&0*6LT_O5F(VCC<$SVR\
M?QN[L<?>'[2ZC<_M!FD?-N7>AR1@1%\G.-&W&VF#MQOI&":W)^_?VNX%B>*)
MQ]ZM^#3LNX$4\V&]I SC38!F Q[/M;'=:.C123W@ <,&[KB.O;$P_=.U;1:(
M/Z'!(6B#T+52:,?Q"6)K.PD%G7K5GMY#J'I=/OO;WQ]_,@X'XW.E^7%H329C
MDW]N-59(0'T<F[GU5@"3F#1A\B'UVH'-QA_99(6X]KN5KM7KG',^;)^%C5;U
MN^J.*=TYB"N-GMI35]Z#O*K5DJ[IM;<;<_ ])+@-T(<VZL0=C_:G8$H#X^3T
MP&I.E"\'1\.?D\^#K</]?D]#,!WJ1>P*A!OSR 768B$H8Q:]?XMR78^$' +(
M1,AY?2!8$SE?RGE<'D?V2O88N>C=2N3Z0X\AYVQ<ZE-\C'@2BD^">^L96L0<
M?@LM>4=,D##_Y-KXV7%92,0DV$*ET6Q_G*?@Y9??YU_-]SX$]'$[_P1"%L;;
M8$'>(YR2 O_I^7NS9U,P[6N:YD_RS_D@&W.(RK$Z1>-&05:NR)5/Q]+(M<%>
MJHKR[^:0VFAG)8\Y,7PCERJS[T*W/YA]R2,7*0$#>4"2"R&4A7XMC]&P;O)X
ML'EYB"MO^B#\ R9Z+X.E+*<J8)AWY<"\)(?ZKC>IO^FZ/HO((1N1$^[3X,UZ
M^@W\C@ ;SIM-T3IR?S(8#3K*@0=(8N[7U<)7J&_PL\E#P,VLQ9A$W'-M\D]J
M;//GV%R3M<HPOO0\55_U3'-%Z',4(4]A@8<7;N2:K@=<DHD4-/_O'UU32IMO
M-_ U(,_PON:-G"!1S^T'=0M8DX6W K-R>S"I$,@>U2W'JE#:JZF5:J^L,:-G
M:HK3*U&FJ&7;4ARS@OJ<+FMBY@+DZ_!(?!RE7&9RSX:VIX?M;FN;=+J-;JOS
M=L-<)O[O &:GU3P]:7?;K0YI'&Z3UM?F7N-PMT6:1P<'[4ZG?73X!&!7%\/^
MI='9:Q_N=H\.U\FVW)3!(:B4C27#NYC7J\L42?W.:)W'X\[1R0$1:'LXGV$[
M"Z.ZPM5#Z3ZD8=C[]N.T\OE8^U ]99.AR?R.LC4Q1C? JTL?4R)?]B=>$M'O
M699 "YRT#KODI'5\=-)]>3)TS^@\3L(HH4%,8@Y!N(620]02X2%1*ZOV&N$.
MB0<,'R4A."P 9FML#6C09Z1AQ?A8-4KE5S)<!I/@_Z7T]TUJ#=U9Q.0)&_(P
M)JOY9_ =/<!X3-@%YG5"\9C9:_6'T8%I%/]N!<+^N@T@2#YT.4#-*-ET(DT
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M]U:(CI)-&OO=]9DD>9ADBPI22,+L?GI=])]E-XJSQ@!C*),](!H'@@VXQ_M
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M\GVFIG?K;'?M",89XT8%$LZ%A1)EYV9XY2,QJ1P^A>>!AW57&-//G@JZR_R
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MEY =<>I1.W?Z;^$SHZJP51H>"JIV8J_  >ZG,'*0A_U$&;Z81GEBG#6N]GF
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M\_?5QF;KWW\C__\ZB#K^GP!02P,$%     @ -FC(7/LEAO #&@  8(P  !@
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M<7FDX]7RWM]K,A[N>PTICYZ_,Y&;:R=RTT'/ +X/%+BC^*I"(Q9[-9RE0%5
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M=F$M,C R-C V,#AX.&LN:'1M4$L! A0#%     @ -FC(7+M9'(G (0  DR,
M !<              ( !H2L  &UT=F$M,C R-C V,#AX.&LP,#$N:G!G4$L!
M A0#%     @ -FC(7/LEAO #&@  8(P  !@              ( !EDT  &UT
L=F$M,C R-C V,#AX97@Y.60Q+FAT;5!+!08     !@ & )(!  #/9P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>mtva-20260608x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mtva-20260608.xsd" xlink:type="simple"/>
    <context id="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001638287</identifier>
        </entity>
        <period>
            <startDate>2026-06-08</startDate>
            <endDate>2026-06-08</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_SqoopIkrAE6Z1ixaaFMt5A_1_1">0001638287</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_-h9RUMcCy0WMOpzyVhBNLg_2_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_YjU5VP2J6UeypbemS0By9w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_zooDrWazp0yv8FMlORHesQ">2026-06-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_1MDtTkcDF0iYNLARDXagnw">METAVIA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_1H_O2LZS5kGy6UozS1u65Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_bMXOiZLJckmy1rip9B51wQ_1_2">001-37809</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_hgKFsw_nH0KFCLOzXjlhEg_1_4">47-2389984</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_S-7nqFAyMEyRkoUlv5LjAw">545 Concord Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_Vy62P6rZSUOliaXrouUT4A">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_s32JPmU-BEqdZxPYEqfCUg">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_IIq8c3NjKUelN6LkTFTI7g">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_Qmc3ip2T1UuU8uZOM-cgMQ_1_2">02138</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_FcmgICg0SU-tgq-1XbYy6g">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_aTgjmJJf_EySkyGw69ZHaQ">702-9600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_3HtLSBcsN0eC2LhvoVkVuw_1_0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_6cZmtYlLtEuLk2g3y0gAPQ_2_0">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_RTpuoD_Iz0uSMTCaAPK8Dg_3_0">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_Oxjp6qu_HU6UdynmXrDOPw_4_0">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_wPjTheSf7UmqrX1fcvMHGg_2_0">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_fHL5uVN3k0OdOklrUUwzIQ_2_2">MTVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Tc_xt7saI8W30i9T08lhtf95w_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_6_8_2026_To_6_8_2026_mLxQ9Nhxq0CKpcyyxboVEA"
      id="Narr_jGmNcBDe40qw5DnSFTw9vQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
